VivaChek

What VivaChek does

VivaChek (杭州微策生物技术股份有限公司) is a privately-held Chinese POCT (Point-of-Care Testing) manufacturer founded in August 2013 in Hangzhou's Linping District, with a workforce of 501–1,000 employees. The company designs, manufactures, and sells electrochemical biosensor-based diagnostic devices — its foundation is a proprietary single-layer 8-electrode test strip using FAD-GDH dehydrogenase chemistry, with clinical-grade interference resistance and EN ISO 15197:2015 accuracy. The product portfolio spans blood glucose meters (830/740/790 4G/Pro/NB-IoT 5G series), multi-parameter glucose/ketone/uric acid analyzers, lactate and uric acid single-parameter meters, veterinary meters (VQpet/VetSight), colloidal gold rapid tests (FOB, COVID-19/flu A/B combo, Strep A, HbA1c), hair drug testing analyzers, dry fluorescence immunoassay systems (VIM2000/VIM3000) with associated biomarker kits, and the VivaChek Cloud chronic disease management platform. NB-IoT/4G/Bluetooth/WiFi connectivity is integrated across the meter line for automatic data upload to the cloud platform.

The commercial model is hardware-anchored with a recurring consumables (test strips) tail, organized around four customer segments: (1) domestic tier-2-and-above hospitals and provincial health commissions (e.g., Qinghai chronic disease program) via field sales and direct distributor relationships; (2) individual consumers/home users via pharmacy chains, Tmall, and WeChat mini-programs under the VivaChek Ino, 好糖, and VQpet sub-brands; (3) international distributors and government health agencies (NHS prescribing directory, Sri Lanka and Moldova Ministries of Health) across 140+ countries; and (4) law enforcement/government for hair drug testing. Wholly-owned overseas subsidiaries in the United States, Hong Kong, India, and Singapore anchor the export business, complemented by Greylynx (辉瓴生物) for infectious disease rapid tests. Pricing is contact-based and not publicly disclosed; revenue mix is dominated by hardware shipments and consumable reorders rather than disclosed SaaS subscriptions, although the cloud platform supports recurring data service revenue.

The company holds US FDA 510(k) clearance for six VivaChek Ino glucose meter models (Dec 2018) and VivaChek Link Plus 4G (Dec 2023); EU IVDR Class C CE certification (Jan 2024); MDSAP five-country certification (Apr 2021); and additional NMPA, MHRA, TGA, and HSA approvals. As of December 2024, it holds 263 registered trademarks and 209 granted patents (30 invention patents). Strategic partners include Shenzhen Gaotejia Investment Group (2016), Kailian Medical Technology (2020 — insulin pump integration), and Guangdong Lifesense Medical Electronics (2023 — channel and product development). National recognitions include Specialized, Refined, and Innovative 'Little Giant' (2023) and Zhejiang Provincial Enterprise Technology Center (Jan 2026). Revenue is not publicly disclosed.

Name

VivaChek

Legal name

杭州微策生物技术股份有限公司

Website

https://vivachek.com.cn

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

VivaChek is a Hangzhou-based Chinese POCT manufacturer founded in 2013 that designs electrochemical biosensor blood glucose meters, multi-parameter glucose/ketone/uric acid analyzers, rapid infectious disease tests, and the VivaChek Cloud chronic disease management platform, serving hospitals, consumers, and government health agencies in 140+ countries.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostic Devices (In-Vitro Diagnostics)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB)

akta.pro secondary industries

Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Blood glucose monitoring
• Point-of-care diagnostics
• POCT test strips
• Multi-parameter analyzers
• Rapid diagnostic tests

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. POCT Diagnostic Instruments and Consumables: 微策生物 generates revenue primarily from the sale of POCT diagnostic instruments (blood glucose meters, multi-analyte analyzers) and their corresponding consumable test strips. Products are sold globally through distributors, hospital channels, pharmacy chains, and e-commerce platforms.
2. Cloud-based Data Services: 微策云 platform enables remote patient monitoring and data management, supporting the sale of connected IoT devices (5G/4G blood glucose meters) that drive ongoing data service revenue through cloud platform subscriptions.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

VivaChek designs, manufactures, and sells POCT (point-of-care testing) diagnostic instruments and consumables, centered on blood glucose meters and test strips but extending to multi-parameter (glucose/ketone/uric acid) analyzers, lactate analyzers, immunofluorescence analyzers, and colloidal gold rapid test kits (FOB, COVID-19, Strep A, hair drug testing). Products are sold globally to hospitals, pharmacies, consumers, and government health programs, with connected devices feeding data into the VivaChek Cloud chronic disease management platform.

Product overview

VivaChek (微策生物) is a POCT (Point-of-Care Testing) company offering a comprehensive product ecosystem centered on blood glucose monitoring and multi-parameter metabolic detection. The portfolio includes: (1) Core glucose meters (830/840/740/790 4G/NB-IoT 5G series), (2) Multi-parameter analyzers for glucose/ketone/uric acid (including Pro version with HIS/LIS integration), (3) Lactate analyzers for sports health, (4) Veterinary blood glucose/ketone meters (VQpet/VetSight), (5) Colloidal gold rapid tests including fecal occult blood (FOB), COVID-19/flu combo, and Strep A, (6) Fluorescent immunoassay (VIM2000/VIM3000) system with 10+ biomarker test kits, (7) Hair drug detection series, and (8) 微策云 cloud platform enabling real-time data sync and remote monitoring. The company positions itself as a 'smart POCT provider' with products spanning chronic disease management (diabetes, hyperuricemia, ketone monitoring), gastrointestinal early screening, sports health, veterinary diagnostics, and drug testing.

Differentiator

Problem solved

Functional benefit

Brands

• 好糖 (HaoTang): Consumer-oriented blood glucose meter brand featuring the 好糖易可III blood glucose meter. Products use single strip packaging for enhanced safety and stability, satisfying ISO15197 standards.
• 亲宠 (QinChong / VQpet)
• VivaDiag

Products and services

• VivaChek 3-in-1 Blood Glucose/Ketone/Uric Acid Analyzer (微策® 血糖/血酮/尿酸分析仪) Multi-function analyzer that simultaneously detects blood glucose, blood ketone, and uric acid using single-layer 8-electrode FAD-GDH technology with strong anti-interference performance, requiring only 0.5 microliter blood sample and supporting Bluetooth/4G data transmission.
• VivaChek Pro Blood Glucose/Ketone/Uric Acid Analyzer (微策® Pro血糖/血酮/尿酸分析仪) Pro-version multi-function analyzer that syncs glucose/ketone/uric acid test data in 3 seconds with direct HIS/LIS integration, designed for hospital inpatient use with cross-department collaborative management.
• VivaChek 4G Blood Glucose/Ketone/Uric Acid Analyzer (微策® 4G血糖/血酮/尿酸分析仪)

Quantifiable outcome

• Self-monitoring of blood glucose has been clinically proven to increase blood glucose compliance rate by 54.2%
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• 广东乐心医疗电子股份有限公司 (Lifesense Medical Electronics, Stock Code: 300562)coreStrategic or Co-development Partner · 27 February 2023微策生物 and Lifesense Medical signed a strategic cooperation agreement to jointly develop the blood glucose monitoring market. The partnership integrates both companies' core R&D capabilities and channel resources to enhance blood glucose monitoring product sales channels and extend medical services. Both companies share a common vision for the blood glucose monitoring market's broad prospects, combining 微策's POCT technology advantage with Lifesense's intelligent health device capabilities and international sales network.
• 凯联医疗科技（上海）有限公司 (Kailian Medical Technology)coreStrategic or Co-development Partner · 1 June 2020微策生物 and Kailian Medical entered a strategic partnership to develop a semi-closed-loop smart blood glucose management solution. The partnership combines 微策's Bluetooth blood glucose monitoring system with Kailian's smart insulin pump (乐泵) to enable data integration between monitoring and treatment, reducing闭环 insulin pump device algorithm complexity and safety risks. This was the first strategic collaboration between an insulin pump and blood glucose meter manufacturer in China.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Sinocare (三诺生物): Leading Chinese blood glucose monitoring and POCT company, listed on Shenzhen Stock Exchange (300298). Most direct domestic competitor to VivaChek with overlapping hospital and consumer BGM product lines, IVD focus, and Chinese hospital channel presence.
• Acon Laboratories: US-based diagnostics company with strong BGM and rapid test portfolio. Comparable in offering consumer and clinical BGM, IVD rapid tests, and serving international distributors across multiple continents.
• i-SENS: Korean BGM and continuous glucose monitoring company with global distribution including Europe and Asia. Direct competitor in electrochemical blood glucose strips, hospital-grade meters, and multi-parameter analyzers.
• Ascensia Diabetes Care: Switzerland-based BGM specialist (Contour portfolio) spun out from Bayer. Direct competitor in consumer and pharmacy-channel blood glucose monitoring globally, with comparable regulatory footprint in IVDR/FDA.
• Lifesense Medical (乐心医疗): Chinese-listed intelligent health devices company (SZSE: 300562) and VivaChek's strategic partner. Directly comparable in connected BGM and remote monitoring focus, with overlapping IoT-enabled device approach and chronic disease management platform strategy.

Broad incumbents

• Abbott Diabetes Care: Global BGM and continuous glucose monitoring leader (FreeStyle Libre). Comparable in connected diabetes devices and international distribution; sets competitive pressure for IoT-enabled glucose monitoring that VivaChek is pursuing in China.
• Mindray (迈瑞医疗): Largest Chinese medical device company with strong IVD and patient monitoring presence. Comparable hospital channel reach in tiered Chinese hospitals and overlapping POCT/in-vitro diagnostic product lines.
• Roche Diabetes Care: Global leader in blood glucose monitoring under Accu-Chek brand. Sets the technology and regulatory benchmark for the BGM category and competes with VivaChek in hospital BGM and self-monitoring globally.
• Yuyue Medical (鱼跃医疗): Major Chinese medical device manufacturer with broad product portfolio including BGM, blood pressure monitors, and home healthcare. Comparable in hospital channel and consumer BGM but operates across much wider medical device categories at significantly larger scale.

Regional players

• ARKRAY: Japanese clinical diagnostics and BGM company. Comparable in hospital-grade glucose monitoring and urine analysis devices, with strong presence in Asia-Pacific hospital channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/VivaChekBio
• Facebookfacebook.com/VivaChekLabs
• LinkedInlinkedin.com/company/vivachek-biotech-hangzhou-co-ltd-

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivaChek